Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease, with hitherto unknown origin. It ranges from a mild disease course, to progressive hepatitis with fatal outcome.
Antibodies against the asialoglycoprotein receptor (ASGPR) are described in approximately 80 % of all patients with active AIH of types I or II. In contrast to other liver specific autoantibodies, antibodies against ASGPR are a marker of histological activity of liver disease. During therapy with corticosteroids, anti-ASGPR can be used for therapeutic monitoring.
- The only commercially available ELISA with highly purified ASGPR from rabbit liver
- Anti-ASGPR is the only organ specific autoantibody in autoimmune liver disease
- Anti-ASGPR allows the serological follow-up of AIH
- Anti-ASGPR allows a differential diagnosis, to rule out toxic and other inflammatory liver diseases.
Anti-ASGPR is an enzyme immunoassay for the semi-quantitive determination of IgG antibodies against the membrane receptor of asialoglycoproteins in human serum or plasma. The analytical sensitivity is a binding index (BI) of 0.3. The diagnostic specificity, identified from a cohort of healthy blood donors, is 100 %. The values for intra- and interassay precision are in the range of 5 - 9 % (coefficient of variation).
Enzyme immunoassay, ELISA
Autoimmune liver disease
IgG antibodies against ASGPR
Dilution of patient samples 1:100 with sample diluent, positive and cut-off controls are ready to use
Semi-quantitative: Binding index (BI), grey area: 0.9 - 1.1 BI
60 min RT - 30 min RT - 15 min RT in the dark
Tetramethylbenzidine (TMB), 450 nm
Human serum or plasma
Villalta, D., Mytilinaiou, M.G., Elsner, M., Hentschel, C., Cuccato J., Somma, V., Schierack, P., Roggenbuck D. and Bogdanos D.P. Autoantibodies to asialoglycoprotein receptor (ASGPR) in patients with autoimmune liver diseases. Clin. Chim. 2015; Acta, 450, 1-5.
Hausdorf, G., Roggenbuck, D., Feist, E. et al. Autoantibodies to asialoglycoprotein receptor (ASGPR) measured by a novel ELISA – revival of a disease-activity marker in autoimmune hepatitis. Clin. Chim. 2009; Acta, 408, 19-24.